Ophthalmic drug is that the administration of a drug to the eyes, most typically as an eye fixed drop formulation. Topical formulations are wont to combat a mess of diseased states of the attention. These states may include bacterial infections, eye injury, glaucoma, and dry eye. However, there are many challenges related to topical delivery of medicine to the cornea of the attention. The most important factor that has got to be taken under consideration when designing any sort of drug delivery device, and specifically ocular devices, is that the release rate of a drug.Ophthalmic Drugs Market was valued at US$ 39.5 Billion in 2024 and is projected to grow at a CAGR of 4.70% to reach US$ 60.2 Billion by 2034.

The report " Ophthalmic  Drugs Market, By Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others), By Therapeutic Class (Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) - Trends, Analysis, and Forecast till 2034”

Key Highlights:

• In 2021, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), announced its launch of the first available generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%, approved by the US Food and Drug Administration to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. Brinzolamide ophthalmic suspension 1% works by decreasing the amount of fluid within the eye.
• IN 2019, Sun Pharmaceutical Industries Ltd. announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the U.S. Food and Drug Administration (FDA)

Analyst View:

Increasing incidence and prevalence of eye related disorders like presbyopia, degeneration, and diabetic retinopathy among the aging population. With the introduction of ophthalmic devices equipped with sophisticated technologies, people are increasingly choosing ophthalmic surgeries to correct their eye related disorders. Lack of insurance amongst population especially within the developing countries or lack of insurance covering all kinds of IOLs or contact in developed countries may be a significant challenge faced by the ophthalmology industry.

Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Ophthalmic  Drugs Market, By Disease Indication (Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others), By Therapeutic Class (Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores), and By Region (North America, Europe, Asia-Pacific, Latin America, and Middle East and Africa) - Trends, Analysis, and Forecast till 2034”

Key Market Insights from the report:

Ophthalmic Drugs Market was valued at US$ 39.5 Billion in 2024 and is projected to grow at a CAGR of 4.70% to reach US$ 60.2 Billion by 2034.  The Ophthalmic drugs market report segments the market on the basis of disease indication, therapeutic class, distribution channel, and region.

• On the basis of Disease Indication, the Ophthalmic drugs market is segmented into Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders (Wet Age-related Macular, Degeneration, Dry Age-related Macular Degeneration, Diabetic Retinopathy, and Others).
• On the basis of Therapeutic Class, the target market is segmented into Anti-inflammatory Drugs (Nonsteroidal Anti-inflammatory Drugs and Steroids), Anti-infective Drugs (Anti-fungal Drugs, Anti-bacterial Drugs, and Others), Anti-glaucoma Drugs (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication, and Others), Anti-allergy Drugs, Anti-VEGF Agents, and Others).
• On the basis of Distribution Channel, the target market divided into Hospital Pharmacies, Online Pharmacies, and Independent Pharmacies and Drug Stores.
• Based on region the Ophthalmic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The global market in North America region is seen to have a matured growth since this market correlates with the increasing growth rate of eye disease. In North America region is the dominating region due to the U.S. is the largest share of market holder of the ophthalmic drugs. In U.S., FDA gives approval to the specific indication, tax credits for drugs.

Competitive Landscape:

Key players in the Ophthalmic  drugs market includes, Santen Pharmaceutical Co., Ltd., Bausch & Lomb Inc. (Valeant Pharmaceuticals International, Inc.), Shire Plc, Alcon (Novartis AG), Genentech, Inc., Allergan, Plc, Sun Pharmaceutical Industries Limited, Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

To know more

Contact Us:

Sales

Prophecy Market Insights

 U.S.  1 860 531 2574

RoW: 917775049802

Email- sales@prophecymarketinsights.com

Website- www.prophecymarketinsights.com